

ESTTA Tracking number: **ESTTA1417436**
Filing date: **02/25/2025**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD

Applicants	Bridge Biotherapeutics Inc.
Application serial no.	97411368
Application filing date	05/15/2022
Mark	KYRIX
Date of publication	12/31/2024
Potential opposer's Correspondence information	ELIZABETH K. RUCKI GSK 410 BLACKWELL STREET DURHAM, NC 27701 UNITED STATES Primary email: trademarks@gsk.com 919-353-8081
Docket no.	84322208

60 Day Request for Extension of Time to Oppose for Good Cause

Pursuant to 37 C.F.R. Section 2.102, GlaxoSmithKline Biologicals SA, RUE DE L'INSTITUT 89, RIX-ENSART, B-1330, BELGIUM respectfully requests that he/she/it be granted an additional 60-day extension of time to file a notice of opposition against the above-identified mark for cause shown.

Potential opposer believes that good causes are established for this request by:

- The potential opposer needs additional time to investigate the claim
- The potential opposer needs additional time to confer with counsel

The time within which to file a notice of opposition is set to expire on 03/01/2025. GlaxoSmithKline Biologicals SA respectfully requests that the time period within which to file an opposition be extended until 04/30/2025.

Respectfully submitted,
/Elizabeth K. Rucki/
Eliabeth K. Rucki
trademarks@gsk.com
02/25/2025